ICU MEDICAL INC/DE
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
(a) None.
(b) None.
(c) The following table shows any“Rule 10b5-1 trading arrangement” or“non-Rule 10b5-1 trading arrangement,” each as defined in Item 408(a) of Regulation S-K and intended to satisfy the Rule 10b5-1 affirmative defense, adopted, modified, or terminated by our directors or "officers" (as defined in Rule 16a-1(f) under the Exchange Act) during the three months ended June 30, 2026.
| Name/Title | Action | Type of Plan | Adoption Date | End Date | Aggregate Number of Securities to be Sold | Plan Description |
|---|---|---|---|---|---|---|
| Brian Bonnell, Chief Financial Officer | Adopted | Rule 10b5-1 trading plan | June 1, 2026 | June 1, 2027 | 24,535 | Sale of vested time-based and performance-based restricted shares. |
| Virginia Sanzone, CVP, General Counsel | Adopted | Rule 10b5-1 trading plan | June 4, 2026 | June 4, 2027 | 4,856 | Sale of vested time-based and performance-based restricted shares. |
Other than as disclosed above, no other officer (as defined in Rule 16a-1(f) under the Exchange Act) or director of the Company adopted, modified, or terminated a "Rule 10b5-1 trading arrangement" or “non-Rule 10b5-1 trading arrangement,” each as defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.